Prostate cancer is the most widely diagnosed disease in men worldwide and is currently ranked as one of the top five cancers in both incidence and mortality. The disease represents significant challenges as prostate cancer has a low survival rate and poor prognosis. Therefore, studies are required to identify how imaging techniques can be utilized for early detection and to assess the evolution of metastasis during treatment.
Primary methods for diagnosis include prostate-specific antigen (PSA) blood examinations and digital rectal examination (DRE) which are confirmed using transrectal ultrasound(TRUS)-guided systematic prostate biopsy. However, this technology is limited due to the low sensitivity and specificity in addition to TRUS-guided biopsy failing to detect approximately 20% of prostate cancer cases. Therefore, there have been developments in the field of imaging in prostate cancer including multiparametric magnetic resonance imaging (MpMRI) but they have been found to be time consuming and expensive. However, cognitive fusion which is a process involving the examination of MRI images before the ultrasound-guided assessment reduces the cost. Technology including MRI-TRUS fusion guided-targeted biopsy (MRI-TB) combines mpMRI’s high accuracy in the detection of cancer lesions and has been found to enhance prostate cancer detection in patients.
This Research Topic aims to generate a discussion on how magnetic resonance imaging aids the detection of prostate cancer and the impact it can have the survival rate and mortality. We welcome Original Research, Reviews, Systematic Reviews, Mini-Reviews and Case Reports.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Prostate cancer is the most widely diagnosed disease in men worldwide and is currently ranked as one of the top five cancers in both incidence and mortality. The disease represents significant challenges as prostate cancer has a low survival rate and poor prognosis. Therefore, studies are required to identify how imaging techniques can be utilized for early detection and to assess the evolution of metastasis during treatment.
Primary methods for diagnosis include prostate-specific antigen (PSA) blood examinations and digital rectal examination (DRE) which are confirmed using transrectal ultrasound(TRUS)-guided systematic prostate biopsy. However, this technology is limited due to the low sensitivity and specificity in addition to TRUS-guided biopsy failing to detect approximately 20% of prostate cancer cases. Therefore, there have been developments in the field of imaging in prostate cancer including multiparametric magnetic resonance imaging (MpMRI) but they have been found to be time consuming and expensive. However, cognitive fusion which is a process involving the examination of MRI images before the ultrasound-guided assessment reduces the cost. Technology including MRI-TRUS fusion guided-targeted biopsy (MRI-TB) combines mpMRI’s high accuracy in the detection of cancer lesions and has been found to enhance prostate cancer detection in patients.
This Research Topic aims to generate a discussion on how magnetic resonance imaging aids the detection of prostate cancer and the impact it can have the survival rate and mortality. We welcome Original Research, Reviews, Systematic Reviews, Mini-Reviews and Case Reports.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
